Based on the encouraging preclinical and early clinical data, we administered osimertinib 80 mg orally at a reduced frequency on a compassionate basis to patients with EGFR mutant lung cancer who were unable to afford full dose osimertinib, refused or had progressed on intravenous chemotherapy and did not have any other treatment options available. The gene discussed is EGFR; the disease is lung carcinoma.